An Intermediate Coronary Stenosis: FFR-Guided Decision or Treat the Angiogram Alone?
The angiogram alone can't say whether this lesion is actually causing his symptoms — and he's made clear he doesn't want to leave with an answer that sounds like wait and see.
T.W., a 67-year-old man, a retired auto mechanic, spent forty years diagnosing engines by feel and instrument reading together — a compression test that came back marginal never satisfied him without a second measurement to settle it. That same instinct is coloring how he's approaching his own diagnosis. He's had three months of exertional chest tightness, reproducible at roughly the same point on his daily walk, that brought him to angiography after his symptoms didn't improve on an initial trial of a beta-blocker and a long-acting nitrate.
The angiogram found a 60–70% stenosis in his proximal LAD — the kind of lesion that sits squarely in the range where visual assessment alone doesn't reliably predict whether it's actually causing his symptoms. He has no prior MI, his ejection fraction is normal, and aside from the hypertension he's carried for two decades, he has no other significant comorbidity. What's actually being debated in the cath lab isn't whether the lesion is real — the angiogram settles that — but whether pressure-wire measurement across it, fractional flow reserve, should decide whether he leaves with a stent or leaves with an escalated medical regimen and the same lesion still in place. The measurement itself is a ratio: distal coronary pressure divided by aortic pressure at maximal hyperemia, with a value at or below 0.80 taken as evidence that the lesion is genuinely limiting flow and anything above it treated as not. He has said plainly, more than once, that he doesn't want to be sent home with an ambiguous lesion and a 'let's see how you do' plan — the closest thing to a marginal compression test he can imagine, and not something his own working life ever let him leave unresolved.
In the cath lab, wire across the lesion
The FAME trial evidence here is about as settled as anything in interventional cardiology gets: using a cutoff of 0.80 or less to define a significant lesion, FFR-guided decision-making in intermediate lesions reduces unnecessary stenting without worsening outcomes compared to treating based on angiographic appearance alone. I want to measure FFR across this lesion before deciding anything, rather than stent it because it looks borderline-severe on the angiogram.
If the lesion were unambiguously severe — 90% or tighter — I wouldn't be proposing this at all; FFR is specifically useful in exactly this intermediate range where visual assessment is least reliable, not as a routine step for every lesion we find.
I don't disagree with the evidence, but I want to name the practical problem: if FFR comes back negative, his medical therapy isn't actually maximized yet. He's on a modest beta-blocker dose and a nitrate, and we haven't tried adding a calcium channel blocker or increasing his beta-blocker before concluding this lesion isn't the answer. A negative FFR shouldn't just mean 'no stent' — it should mean a real trial of escalated anti-anginal therapy, or he's going to be back with the same symptoms and no plan.
That's a fair point about escalating therapy first, but I don't think it argues against measuring FFR now — if anything, knowing whether this lesion is hemodynamically significant tells us how hard to push medical therapy versus how quickly to reconsider intervention if his symptoms don't respond.
I'd frame the plan around what each FFR result should actually trigger, since he's told us directly that ambiguity is the outcome he wants to avoid. If FFR is 0.80 or below — physiologically significant — stenting proceeds and that's a clear answer, with clopidogrel added to his aspirin as dual antiplatelet therapy afterward. Clopidogrel specifically, not ticagrelor or prasugrel: this is stable coronary disease, not an acute coronary syndrome, and the more potent agents carry bleeding risk without a matching indication here. If it's negative, the plan isn't 'nothing changes'; it's uptitrating his beta-blocker to its target dose and adding amlodipine, with a defined follow-up to see whether that resolves his symptoms. Either branch gives him the definitive plan he's asked for, which the angiogram alone couldn't.
Agreed: FFR measured across the lesion this procedure, with the branch explained to him directly before the wire crosses the lesion so the plan doesn't feel open-ended either way it comes back.
Stenting proceeds in the same procedure, with clopidogrel added to his aspirin afterward; no separate return trip required.
Metoprolol uptitrates to target dose, amlodipine is added, and he returns in six weeks to confirm his symptoms have actually resolved on medical therapy.
Either branch gives him a defined next step today, which was the outcome he'd asked for most directly.